

By HAND DELIVERY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 6448

Application No.: 10/091,268

Group Art Unit: 1646

Filed: March 4, 2002

Examiner: To Be Assigned

For: METHODS OF
ADMINISTERING/DOSING CD2
ANTAGONISTS FOR THE PREVENTION
AND TREATMENT OF AUTOIMMUNE
DISORDERS OR INFLAMMATORY
DISORDERS

Attorney Docket No.: 10271-054

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01-A68, B01-B51, and C01-C164** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **A01-A68, B01-B51, and C01-C164** are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application. While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicants particularly direct the Examiner's attention to references A01, A05, A10, A12, A14, A19, A26, A27, A43, B01, B02, B07, B14, B26, B29, B30, B33, C01-C05, C07, C12, C17, C19, C23, C26, C33, C36-C39, C41-C43,

C45, C46, C48, C52, C57, C58, C60, C61, C64, C69, C73, C74, C78, C81-C83, C89-92, C94, C95, C99-C102, C104, C106, C108, C110, C112, C115, C117, C119, C120, C123, C125-C128, C131, C133, C137, C140-C144, C147, and C160.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. Please charge any required fee to Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,


Date February 24, 2004

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

By: Jennifer J. Chheda
Reg No. 46,617




LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)


ATTY. DOCKET NO. 10271-054-999	APPLICATION NO. 10/091,268
APPLICANT Dingivan	
FILING DATE March 4, 2002	GROUP 1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLA SS	FILING DATE IF APPROPRIATE
	A01	2003/0044406	3/6/03	Dingivan			
	A02	6,340,459	1/22/02	Yellin et al.			
	A03	6,331,415	12/18/01	Cabilly et al.			
	A04	6,277,375	8/21/01	Ward			
	A05	6,162,432	12/19/00	Wallner et al.			
	A06	6,153,628	11/28/00	Jin et al.			
	A07	6,037,454	3/14/00	Jardieu et al.			
	A08	5,989,463	11/23/99	Tracy et al.			
	A09	5,969,108	10/19/99	McCafferty et al.			
	A10	5,951,983	9/14/99	Bazin et al.			
	A11	5,939,598	8/17/99	Kucherlapati et al.			
	A12	5,928,643	7/27/99	Wallner et al.			
	A13	5,916,597	6/29/99	Lee et al.			
	A14	5,914,111	6/22/99	Wallner et al.			
	A15	5,912,015	6/15/99	Bernstein et al.			
	A16	5,908,626	6/1/99	Chang et al.			
	A17	5,844,095	12/1/98	Linsley et al.			
	A18	5,821,047	10/13/98	Garrard et al.			
	A19	5,817,311	10/6/98	Bazin et al.			
	A20	5,814,318	9/29/98	Lonberg et al.			
	A21	5,807,715	9/15/98	Morrison et al.			
	A22	5,783,181	7/21/98	Browne et al.			
	A23	5,780,225	7/14/98	Wigler et al.			
	A24	5,750,753	5/12/98	Kimae et al.			
	A25	5,733,743	3/31/98	Johnson et al.			
	A26	5,730,979	3/24/98	Bazin et al.			
	A27	5,728,677	3/17/98	Wallner et al.			



	A28	5,723,125	3/3/98	Chang et al.		
	A29	5,698,426	12/16/97	Huse		
	A30	5,679,377	10/21/97	Bernstein et al.		
	A31	5,661,016	8/26/97	Lonberg et al.		
	A32	5,658,727	8/19/97	Barbas et al.		
	A33	5,633,425	5/27/97	Lonberg et al.		
	A34	5,625,126	4/29/97	Lonberg et al.		
	A35	5,622,929	4/22/97	Willner et al.		
	A36	5,601,819	2/11/97	Wong et al.		
	A37	5,585,089	12/17/96	Queen et al.		
	A38	5,580,717	12/3/96	Dower et al.		
	A39	5,573,920	11/12/96	Randle		
	A40	5,571,698	11/5/96	Ladner et al.		
	A41	5,569,825	10/29/96	Lonberg et al.		
	A42	5,565,332	10/15/96	Hoogenboom et al.		
	A43	5,547,853	8/20/96	Wallner et al.		
	A44	5,545,806	8/13/96	Lonberg et al.		
	A45	5,530,101	6/25/96	Queen et al.		
	A46	5,516,637	5/14/96	Huang et al.		
	A47	5,447,851	9/5/95	Beutler et al.		
	A48	5,427,908	6/27/95	Dower et al.		
	A49	5,413,923	5/9/95	Kucherlapati et al.		
	A50	5,403,484	4/4/95	Ladner et al.		
	A51	5,359,046	10/25/94	Capon et al.		
	A52	5,349,053	9/20/94	Landolfi		
	A53	5,336,603	8/9/94	Capon et al.		
	A54	5,225,539	7/6/93	Winter		
	A55	5,223,409	6/29/93	Ladner et al.		
	A56	5,128,326	7/7/92	Balazs et al.		
	A57	5,122,464	6/16/92	Wilson et al.		
	A58	5,112,946	5/12/92	Maione		
	A59	4,980,286	12/25/90	Morgan et al.		
	A60	4,925,648	5/15/90	Hansen et al.		
	A61	4,816,567	3/28/89	Cabily et al.		
	A62	4,816,397	3/28/89	Boss et al.		



A63	4,716,111	12/29/87	Osband et al.		
A64	4,714,681	12/22/87	Reading		
A65	4,676,980	6/30/87	Segal et al.		
A66	4,526,938	7/2/85	Churchill et al.		
A67	4,474,893	10/2/84	Reading		
A68	4,444,887	4/24/84	Hoffmann		


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 00/78814	12/28/00	PCT				
	B02	WO 00/12113	3/9/00	PCT				
	B03	WO 99/23105	5/14/99	PCT				
	B04	WO 99/20253	4/29/99	PCT				
	B05	WO 99/15154	4/1/99	PCT				
	B06	WO 99/04813	2/4/99	PCT				
	B07	WO 99/03502	1/28/99	PCT				
	B08	WO 98/50433	11/12/98	PCT				
	B09	WO 98/46645	10/22/98	PCT				
	B10	WO 98/33919	8/6/1998	PCT				
	B11	WO 98/24893	6/11/98	PCT				
	B12	WO 98/23289	6/4/98	PCT				
	B13	WO 98/16654	4/23/98	PCT				
	B14	WO 98/07444	2/26/98	PCT				
	B15	WO 97/34911	9/25/97	PCT				
	B16	WO 97/34631	9/25/97	PCT				
	B17	WO 97/33899	9/18/97	PCT				
	B18	WO 97/13844	4/17/97	PCT				
	B19	WO 96/34096	10/31/96	PCT				
	B20	WO 96/33735	10/31/96	PCT				
	B21	WO 96/22024	7/25/96	PCT				
	B22	WO 96/20698	7/11/96	PCT				
	B23	WO 96/04388	2/15/96	PCT				
	B24	WO 95/20401	8/3/95	PCT				
	B25	WO 95/15982	6/15/95	PCT				
	B26	WO 94/20619	9/15/94	PCT				
	B27	WO 93/17715	9/16/93	PCT				
	B28	WO 93/11236	6/10/93	PCT				
	B29	WO 93/06866	4/15/93	PCT				
	B30	WO 93/06852	4/15/93	PCT				
	B31	WO 92/22324	12/23/92	PCT				
	B32	WO 92/18619	10/29/92	PCT				
	B33	WO 92/16622	10/1/92	PCT				
	B34	WO 92/08802	5/29/92	PCT				


	B35	WO 92/05793	4/16/92	PCT				
	B36	WO 92/01047	1/23/92	PCT				
	B37	WO 91/10741	7/25/91	PCT				
	B38	WO 91/10737	7/25/91	PCT				
	B39	WO 91/05548	5/2/91	PCT				
	B40	WO 91/09967	7/11/91	PCT				
	B41	WO 91/06570	5/16/91	PCT				
	B42	WO 91/00360	1/10/91	PCT				
	B43	WO 90/02809	3/22/90	PCT				
	B44	WO 89/01036	2/9/89	PCT				
	B45	WO 88/07089	9/22/88	PCT				
	B46	WO 86/05807	6/10/86	PCT				
	B47	EP 592106	4/13/94	EP				
	B48	EP 519596	12/23/92	EP				
	B49	EP 394827	10/31/90	EP				
	B50	EP 367166	5/9/90	EP				
	B51	EP 239400	9/30/87	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	GenBank Accession No.: AH002740 human T-cell surface antigen T11 (CD2) gene, exon 1, clone PB2
	C02	GenBank Accession No.: CAA29622
	C03	GenBank Accession No.: E12817 cDNA encoding human LFA-3
	C04	GenBank Accession No.: M16445 human surface antigen CD2 mRNA, complete cds
	C05	GenBank Accession No.: X06143 murine mRNA for T11 protein
	C06	Abrams et al., 2000, "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells," J. Exp. Med. 192(5):681-694
	C07	Adkins et al., A phase I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-CD2 monoclonal antibody, in the initial treatment of at least grade II acute graft-versus host disease. Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Blood 2000 96:476A Poster Board No. 784
	C08	Ames et al., 1995, "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins," J. Immunol. Methods 184:177-186
	C09	Anasetti et al., 2000, "Anti-CD3 F(AB') ₂ prevents Graft-Versus-Host Disease by selectively depleting donor T cells activated by recipient alloantigens," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
	C10	Arnon et al., 1985, "Monoclonal antibodies for immunotargeting of drugs in cancer therapy", in: <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., eds., Alan R. Liss, Inc., pp. 243-256
	C11	Asadullah et al., 1999, "Interleukin-10 in Cutaneous Disorders: Implications for Its Pathophysiological Importance and Therapeutic Use," Arch. Dermatol. Res. 291(12):628-36
	C12	Ashcroft et al., 2000, "Therapeutic strategies for psoriasis," J. Clin. Pharm. Ther. 25(1):1-10
	C13	Ashkenazi et al., 1991, "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," Proc. Natl. Acad. Sci. USA 88:10535-10539
	C14	Ausubel et al., eds., 1994, Current Protocols in Molecular Biology, John Wiley & Sons, NY, pp. 10.16.1 and 11.2.1
	C15	Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, NY, pp. 2.10.3 and 6.3.1 - 6.3.6
	C16	Bauer et al., 1999, "Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis," J. Pharmacokinet. Biopharm. 27(4):397-420
	C17	Besse et al., 1997, "Prevention of Rejection with BTI-322 After Renal Transplantation (Results at 9 Months)" Transplantation Proc. 29:2425-2426
	C18	Better et al., 1988, "Escherichia coli secretion of an active chimeric antibody fragment," Science 240(4855):1041-1043
	C19	Branco et al., 1999, "Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells," Transplantation 68(10):1588-1596
	C20	Brinkmann et al., 1995, "Phage display of disulfide-stabilized Fv fragments," J. Immunol. Methods 182(1):41-50




C21	Buchwald et al., 1980, "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," Surgery 88(4):507-516
C22	Burton and Barbas, 1994, "Human antibodies from combinatorial libraries," Adv. Immunol. 57:191-280
C23	Camisa, 2000, "Psoriasis: A Clinical Update on Diagnosis and New Therapies," Cleve Clin. J. Med. 67(2):105-106
C24	Carpenter et al., 2000, "Humanized non-FCR-binding anti-CD3 antibody as therapy for glucocorticoid refractory acute GVHD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305
C25	Cathcart et al., 1986, "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31
C26	Chisholm et al., 1994, "The effects of an immunomodulatory LFA3-IgG ₁ fusion protein on nonhuman primates," Therapeutic Immunity 1:205-216
C27	Chong, 1996, "Receptors that turn on and turn off natural killer cells," J Heart Lung Transplant. 15(7):675-683
C28	Chiorazzi, 1986, "Human monoclonal antibodies as probes to study autoimmune and allergic disorders," Biotechnology 4:210-218
C29	Chothia et al., 1998, "Structural determinants in the sequences of immunoglobulin variable domain," J. Mol. Biol. 278(2):457-479
C30	Cleek et al., 1997, "Biodegradable polymeric carriers for a bFGF antibody for cardiovascular application," Proc. Intl. Symp. Control. Rel. Bioact. Mater. 24:853-854
C31	Cockett et al., 1990, "High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification," Biotechnology 8(7):662-667
C32	Cohn et al., 1997, "Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production," J. Exp. Med. 186:1737-1747
C33	Couriel et al., 2000, "Infliximab for the treatment of Graft-Versus-Host disease in allogeneic transplant recipients: an update," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 775
C34	Courtenay et al., 1980, "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666-668
C35	Crofford and Wilder, 1993, "Arthritis and autoimmunity in animals," in: <u>Arthritis and Allied Conditions: A Textbook of Rheumatology</u> , McCarty et al., eds., Lee & Febiger, Chapter 30
C36	Davis et al., 1996, "The Structure and Ligand Interactions of CD2: Implications for T-Cell Function," Immunology Today 17(4):177-187
C37	Dehoux et al., 2000, "Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody," Transplantation 69:2622-2633
C38	De La Parra, et al., 1991, "Inhibition of T-Cell Activation by Lo-CD2-a, A Rat monoclonal Antibody Against the Human CD2 Glycoprotein," Belgian Journal of Zoology 121(Supp.1):13 Abstract 16
C39	Devrimci-Ozguven et al., 2000, "The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients," J. Eur. Acad. Dermatol. Venereol. 14(4):267-271
C40	Diasio et al., 1996, "Immunomodulators: Immunosuppressive agents and immunostimulants," in: <u>The Pharmacological Basis of Therapeutics</u> , McGraw-Hill, New York, Ch. 52, pp. 1291-1306
C41	DiSepio et al., 2000, "New Drugs in the Treatment of Psoriasis," Expert Opin Investig Drugs 9(1):79-93
C42	Drew, 2000, "Psoriasis," Primary Care 27(2):385-406
C43	Dumont et al., 1998, "Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T Cells," J. Immunol. 3797-3804
C44	During et al., 1989, "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," Ann. Neurol. 25:351-356
C45	Ellis, 1999, "Quality of Life (QOL) of Amevive TM (LFA3TIP) in patients with chronic plaque psoriasis," Amevive Breakfast Meeting, 12/3/99 and abstract from Br. J. Dermatol. 141:990 Abstract 82
C46	Ellis et al., "Quality of Life (QOL) in Patients with Chronic Psoriasis Treated with AMEVIVE (LFA3TIP)," Poster Presentation
C47	Feldmann, M. 'Cytokine Inhibitors: Biologics'. In: <u>Inflammation: Basic Principles and Clinical Correlates</u> . 3 rd Edition, Ed. Gillian and Synderman. Lippincott Williams & Wilkins (Philadelphia) 1999, pages 1207-1212
C48	Ferrant et al., 1997, "LO-CD2a/BTI322 for Steroid Resistant Graft-Versus-Host Disease," BTI Ref 1979, (Something) Transplant 19(Supp. 1): S181 Abstract P721
C49	Flanders et al., 1999, "Prevention of type 1 diabetes from laboratory to public health," Autoimmun. 29:235-246
C50	Foecking and Hofstetter, 1986, "Powerful and versatile enhancer-promoter unit for mammalian expression vectors," Gene 45:101-105
C51	Foster, 1999, "Relevance of systemic lupus erythematosus nephritis animal models to human disease," Semin. Nephrol. 19(1):12-24
C52	Fredriksson and Pettersson, 1978, "Severe psoriasis--oral therapy with a new retinoid," Dermatologica 157(4):238-244



C53	Gentz et al., 1989, "Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis," Proc. Natl. Acad. Sci. USA 86(3):821-824
C54	Gillies et al., 1989, "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," J. Immunol. Methods 125:191-202
C55	Goodson, 1984, "Dental Applications," in: <u>Medical Applications of Controlled Release</u> , Langer and Wise, eds., vol. 2, Ch. 6, pp. 115-138
C56	Gottlieb et al., 2000, "Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study," J. Am. Acad. Dermatol. 43(4):595-604
C57	Gottlieb et al., 2000, "Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis," J. Am. Acad. Dermatol. 42(3):428-435
C58	Greaves and Weinstein, 1995, "Treatment of psoriasis," N. Eng. J. Med. 332(9):581-588
C59	Greenspan and Bona, 1989, "Idiotypes: structure and immunogenicity," FASEB J. 7:437-444
C60	Griffiths, 1999, "T cell targeting for psoriasis," Amevive Breakfast Meeting, 12/3/99
C61	Guzzo et al., 1996, "Dermatological pharmacology," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Ch. 64, pp. 1593-1613
C62	Hammerling et al., 1981, "Production of hybridomas in the rodent system," in: <u>Monoclonal Antibodies and T-Cell Hybridomas</u> , Elsevier, NY, pp. 563-581
C63	Hansra et al., 2000, "Carrageenan-induced arthritis in the rat", Inflammation 24:141-155
C64	Harari et al., 2000, "Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea", Int. J. Dermatol. 39(12):913-918
C65	Hellstrom et al., 1987, "Antibodies for drug delivery", in: <u>Controlled Drug Delivery 2nd ed.</u> , Robinson et al., eds., Marcel Dekker, Inc. pp. 623-653
C66	Heslop et al., 2000, "ABX-CBL monoclonal antibody in patients with steroid resistant graft versus host disease," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Abstract 305
C67	Holmdahl, 1999, "Autoimmunity: Another pathway towards arthritis," Curr. Biol. 9:R528-530
C68	Howard et al., 1989, "Intracerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg. 71(1):105-112
C69	Husted et al., 1995, "A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis," Clin. Exp. Rheumatol. 13(4):439-443
C70	Inouye and Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli," Nucl. Acids Res. 13(9):3101-3110
C71	Jemec and Wulf, 1997, "The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis," Acta Derm. Venereol. 77(5):392-393
C72	Joliot et al., 1991, "Antennapedia homeobox peptide regulates neural morphogenesis," Proc. Natl. Acad. Sci. USA 88:1864-1868
C73	Kaplon et al., 1996, "Short Course Single Agent Therapy with an LFA-3-IgG1 Fusion Protein Prolongs Primate Cardiac Allograft Survival," Transplantation 61(3):356-363
C74	Karasek, 1999, "Progress in our understanding of the biology of psoriasis," Cutis 64(5):319-322
C75	Kettleborough et al., 1994, "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments," Eur. J. Immunol. 24(4):952-958
C76	Kim and Berstad, 1992, "Experimental colitis in animal models," Scand. J. Gastroenterol. 27(7):529-537
C77	Kostelny et al., 1992, "Formation of a bispecific antibody by the use of leucine zippers," J. Immunol. 148(5):1547-1553
C78	Kozarsky et al., 1993, "An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites," Cell Immunol. 150(2):235-246
C79	Krieger et al., 1997, "The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection," J. Heart Lung Transplant. 16:263-267
C80	Krogh et al., 1999, "Models to study the pathogenesis of thyroid autoimmunity," Biochimie 81(5):511-515
C81	Krueger et al., 2000, "Anti-CD11a Treatment for Psoriasis Concurrently Increases Circulating T-cells and Decreases Plaque T-cells, Consistent with Inhibition of Cutaneous T-cell Trafficking," J. Invest. Dermatol. 115(2):333
C82	Krueger, 1999, "Efficacy and safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis," Amevive Breakfast Meeting 12/3/99
C83	Krueger, 1999, "Phase II trial results of Amevive TM (LFA3TIP) in patients with chronic plaque psoriasis," Br. J. Dermatol. 141:979-980, Abstract 39
C84	Krueger et al., 2000, "Successful in vivo Blockade of CD25 (High-Affinity Interleukin 2 Receptor) on T Cells by Administration of Humanized Anti-Tac Antibody to Patients with Psoriasis," J. Am. Acad. Dermatol. 43(3):448-458


	C85	Lafaille et al., 1994, "High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice," Cell 78(3):399-408
	C86	Lam et al., 1997, "Microencapsulation of recombinant humanized monoclonal antibody for local delivery," Proc. Intl. Symp. Control. Rel. Bioact. Mater. 24:759-760
	C87	Langer and Peppas, 1983, "Chemical and physical structure of polymers as carriers for controlled release of bioreactive agents: a review," J. Macromol. Sci. Rev. Macromol. Chem. and Physics C23(1):61-126
	C88	Langer, 1990, "New methods of drug delivery," Science 249(4976):1527-1533
	C89	Latinne et al., 1997, "BTI-322, An Anti-Human CD2 MAB, Elicits Specific Depletion of T Cells Activated by Anti-TCR VbMAB," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
	C90	Latinne et al., 1996, "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro," Int. Immunol. 8(7):1113-1119
	C91	Lebwohl, 2000, "Advances in psoriasis therapy," Dermatol. Clin. 18:13-19
	C92	Lerut et al., "The Use of Tacrolimus (TAC) and Anti-CD2 Antibody Lo-CD2a (BTI-322) in Adult Liver Transplantation (LT): Preliminary Results of a Prospective Randomized Study," Abstract 102
	C93	Levy et al., 1985, "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," Science 228(4696):190-192
	C94	Li et al., 1995, "CD2 Antigen: Signaling Features and Strategies to Inhibit CD2 Antigen-Derived Signals," in Recent Developments in Transplantation Medicine V.2, Ch. 7, Salomon and Sollinger, eds., pp. 97-121
	C95	Linden et al., 1999, "Psoriasis: Current Perspectives with an Emphasis on Treatment," Am. J. Med. 107(6):595-605
	C96	Logan and Shenk, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," Proc. Natl. Acad. Sci. USA 81(12):3655-3659
	C97	Lonberg and Huszar, 1995, "Human antibodies from transgenic mice," Int. Rev. Immunol. 13(1):65-93
	C98	Lopez-Berestein et al., 1989, "Treatment of systemic fungal infections with liposomal amphotericin B," in: <u>Liposomes in the Therapy of Infectious Disease and Cancer</u> , Lopez-Berestein and Fiedler, eds., Alan R. Liss, NY, pp. 317-327
	C99	Magilavy et al., "Immunopharmacologic effects of AMEVIVE™ (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45RO+) over naïve (CD45RA+) T cells," Poster presentation and abstract from Br. J. Dermatol. 141:990, Abstract 81
	C100	Magilavy et al., 2000, "The Response of Plaque Psoriasis to Amevive™ (LFA3TIP) and the Selective Suppression of Memory/Effector T Cells (CD45RO+) Verses Naïve T Cells (CD45RA+) Is Serum Levels of LFA3TIP," J. Invest. Dermatol. 114(4):776 Abstract 148
	C101	Magilavy et al., 1999, "Pharmacodynamic effects of Amevive™ (LFA3TIP), a LFA-3/igg Fc fusion protein in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naïve (CD45RA+) T cells," Amevive Breakfast Meeting, 12/3/99
	C102	Majeau et al., 1994, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses," J. Immunol. 152(6):2753-67
	C103	Margolis et al., 2000, "Pentostatin: A novel treatment for steroid refractory acute GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 774
	C104	Meier et al., 1995, "Immunomodulation by LFA3TIP, an LFA-3/IgG1 Fusion Protein: Cell Line Dependent Glycosylation Effects on Pharmacokinetics and Pharmacodynamic Markers," Ther. Immunol. 2(3):159-171
	C105	Merck Manual of Diagnosis and Therapy, Seventeenth Edition. Ed. Beers and Berkow. Merck Research Laboratories (Whitehouse Station, NJ), 1999, pages 416-423
	C106	Miller et al., 1993, "Specific Interaction of Lymphocyte Function-Associated Antigen 3 with CD2 Can Inhibit T Cell Responses," J. Exp. Med. 178:211-222
	C107	Mollee et al., 2000, "Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
	C108	Mollereau et al., 1999, "Effects of Anti-CD2 Monoclonal Antibody: CD2- and CD95-Mediated Apoptosis of Human Peripheral T Cells," Transplantation Proc. 31:1245
	C109	Morrison, 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
	C110	Mourad et al., 1997, "BTI-322 for Acute Rejection After Renal Transplantation," Transplantation Proc. 29:2353
	C111	Mullinax et al., 1992, "Expression of a heterodimeric Fab antibody protein in one cloning step," BioTechniques 12(6):864-869
	C112	Nevitt and Hutchinson, 1996, "Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease," Brit. J. Dermatol. 135(4):533-537
	C113	Ning et al., 1996, "Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel," Radiother. Oncol. 39(2):179-189
	C114	Nisonoff, 1991, "Idiotypes: concepts and applications," J. Immunol. 147(8):2429-2438
	C115	Nizet et al. 2000, "The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322," Transplantation 69(7):1420-1428



C116	Order, 1985, "Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: <u>Monoclonal Antibodies for Cancer Detection and Therapy</u> , Baldwin et al., eds., Academic Press, pp. 303-316
C117	Ortonne, 1999, "Recent Developments in the Understanding of the Pathogenesis of Psoriasis," Br. J. Dermatol. 140 Suppl 54:1-7
C118	Padlan, 1991, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," Mol. Immunol. 28(4-5):489-498
C119	Papp et al., 1999, "The treatment of moderate to severe psoriasis with hu124: a new monoclonal antibody," Br. J. Dermatol. 141:980, Abstract 40
C120	Pasquini et al., 2000, "Basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist - as therapy for refractory acute Graft Versus Host Disease (a-GHVD) following bone marrow transplantation (BMT)," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board No. 762
C121	Paul, ed., 1989, <u>Fundamental Immunology</u> 2 nd Ed., Raven Press, NY, pp. 332-336
C122	Persic et al., 1997, "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries," Gene 187(1):9-18
C123	Peters et al., 2000, "Pathophysiology and treatment of psoriasis," Am. J. Health Sys. Pharm. 57(7):645-659
C124	Potter et al., 2000, "Campath 1 H "In the Bag" is an effective method of GHVD prevention in allogeneic stem cell transplantation," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305
C125	Przepiorika et al., "Pharmacokinetics and Safety of BTI-322, a Rat Anti-CD2 Monoclonal Antibody for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," BTI Ref 3623
C126	Przepiorika et al., 1998, "A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," Blood 92(11):4066-4071
C127	Rabinowitz et al., 1995, "In vitro activation leads to the binding of T-cell markers to the surface of B-lymphocytes," Clin. Immunol. Immunopathol. 76(2):148-154
C128	Ratanathathorn et al., 1999, "Pharmacokinetics and Safety of Medi-507, a Humanized Anti-CD2 Monoclonal Antibody in Severe Steroid-Resistant Graft-Versus-Host Disease," International Society for Experimental Hematology, Abstract 119
C129	Riechmann et al., 1988, "Reshaping human antibodies for therapy," Nature 332(6162):323-327
C130	Robert et al., 1999, "Inflammatory skin diseases, T cells, and immune surveillance," New England J of Med. 341(24):1817-1828
C131	Roenigk et al., 1988, "Methotrexate in psoriasis: revised guidelines," J. Am. Acad. Dermatol. 19(1 pt. 1):145-156
C132	Roguska et al., 1994, "Humanization of murine monoclonal antibodies through variable domain resurfacing," Proc. Natl. Acad. Sci. USA 91:969-973
C133	Rouleau et al., 1997, "CD2 Induced Apoptosis of Peripheral T Cells," Transplantation Proc. 29:2377-2378
C134	Ruther and Muller-Hill, 1983, "Easy identification of cDNA clones," EMBO J. 2(10):1791-1794
C135	Saudek et al., 1989, "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J. Med. 321(9):574-579
C136	Sawai et al., 1995, "Direct production of the Fab fragment derived from the sperm immobilizing antibody using polymerase chain reaction and cDNA expression vectors," Am. J. Reprod. Immunol. 34(1):26-34
C137	Schad et al., 1996, "An Anti-CD2 Monoclonal Antibody That Elicits Alloantigen-Specific Hyporesponsiveness," Transplantation Proceedings 28(4):2051-2053
C138	Sefton, 1987, "Implantable pumps," Crit. Rev. Biomed. Eng. 14(3):201-240
C139	Song et al., 1996, "Antibody mediated lung targeting of long-circulating emulsions," PDA J. Pharm. Sci. Technol. 50(6):372-397
C140	Spitzer et al., 2000, "Haploidentical donor bone marrow transplantation for advanced hematologic malignancy following non-myeloablative preparative therapy: role of in vivo T cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy," Blood 96:841A
C141	Squifflet et al., 1997, "BTI-322 for Induction Therap after Renal Transplantation: A Randomized Study," Transplant Proc. 29(1-2):317-319
C142	Squifflet et al., 1997, "A Randomized Study of BTI-322 for the Prevention of Renal Allograft Rejection: One Year Follow Up," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
C143	Stern, 1995, "Epidemiology of psoriasis," Dermatol. Clin. 13(4):717-722
C144	Stern and Laird, 1994, "The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study," Cancer 73(11):2759-2764
C145	Strober, 1985, "Animal models of inflammatory bowel disease--an overview," Dig. Dis. Sci. 30(12 suppl.):3S-10S
C146	Studnicka et al., 1994, "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," Protein Eng. 7(6):805-814



C147	Sultan et al., 1997, "Blockade of CD2-LFA-3 Interactions Protects Human Skin ALlografts in Immunodeficient Mouse/Human Chimeras," Nature Biotechnology 15:759-762
C148	Takahashi et al., 1994, "Human Fas ligand: gene structure, chromosomal location and species specificity," Int. Immunol. 6(10):1567-1574
C149	Thorpe, 1985, "Antibody carriers of cytotoxic agents in cancer therapy: a review," in: <u>Monoclonal Antibodies '84: Biological and Clinical Applications</u> , Pinchera et al., eds., pp. 475-506
C150	Thorpe and Ross, 1982, "The preparation and cytotoxic properties of antibody-toxin conjugates," Immunol. Rev. 62:119-158
C151	Traunecker et al., 1988, "Soluble CD4 molecules neutralize human immunodeficiency virus type 1," Nature 331(6151):84-86
C152	Treat et al., 1989, "Liposome encapsulated doxorubicin: Preliminary results of Phase I and Phase II Trials," in: <u>Liposomes in the Therapy of Infectious Disease and Cancer</u> , Lopez-Berestein and Fiedler, eds., Alan R. Liss, NY, pp. 353-365
C153	Trentham et al., 1977, "Autoimmunity to type II collagen an experimental model of arthritis," J. Exp. Med. 146(3):857-868
C154	Tutt et al., 1991, "Trispecific F(ab') ₃ derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells," J. Immunol. 147(1):60-69
C155	Van Heeke and Schuster, 1989, "Expression of human asparagine synthetase in Escherichia coli," J. Biol. Chem. 264(10):5503-5509
C156	Vie et al., 1992, "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA 89:11337-11347
C157	Wilson et al., 1984, "The structure of an antigenic determinant in a protein," Cell 37(3):767-778
C158	Winter et al., 1962, "Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs," Proc. Soc. Exp. Biol. Med. 111:544-547
C159	Woodward et al., 1996, "Blockade of multiple costimulatory receptors induces hyporesponsiveness," Transplantation 62(7):1011-1018
C160	Xu et al., 2000, "Inhibition of Human Anti-Pig T-Cell Response by Anti-CD2, Anti-CD40L, and CTLA4-Ig: A Comparative Study," Transplantation Proc. 32:926
C161	Yamamoto et al., 1998, "The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats," Endocrinol. 139(3):1411-1419
C162	Yoshitake et al., 1999, "Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption," Proc. Natl. Acad. Sci. USA 96:8156-8160
C163	Zamvil and Steinman, 1990, "The T lymphocyte in experimental allergic encephalomyelitis," Annu. Rev. Immunol. 8:579-621
C164	Zheng et al., 1995, "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," J. Immunol. 154(10):5590-5600



EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	